Advancements in the Formulations and Delivery Systems of Antimalarial Drugs: Challenges and Opportunities in Combating Malaria
DOI:
https://doi.org/10.55544/jrasb.5.3.2Keywords:
Malaria, drug delivery system, Antimalarial drug, liposomeAbstract
The global burden of malaria continues to present serious obstacles to public health, particularly in sub-Saharan Africa and parts of Asia. Traditional antimalarial drugs have been instrumental in combating malaria, but issues such as drug resistance, side effects, and suboptimal bioavailability have prompted the development of innovative drug formulations and delivery systems. Recent advancements in nanotechnology, targeted drug delivery, and controlled-release formulations have enhanced the therapeutic efficacy of antimalarial agents. Nano-carrier systems, such as liposomes, micelles, and dendrimers, offer improved drug stability, targeted action, and reduced toxicity, addressing limitations of conventional treatment regimens. Additionally, transdermal, inhalable, and medication delivery system that are implanted have been explored to improve patient adherence and optimize dosing. The integration of diagnostic tools with therapeutic delivery systems, as seen in combination therapies, allows for better management of drug-resistant malaria. The most effective method for malaria treatment is Artemisinin-based Combination Therapy (ACT) for uncomplicated cases, as it rapidly eliminates parasites and prevents resistance through dual-drug action. For severe or complicated malaria, intravenous artesunate is the gold standard, providing faster parasite clearance and significantly reducing mortality compared to older drugs like quinine. This review highlights the key advancements in the formulation and delivery systems of antimalarial drugs, focusing on the development of novel technologies and their potential to revolutionize malaria treatment, reduce transmission, and mitigate the challenges of resistance and adverse effects.
Downloads
References
Carter R, Mendis KN. Evolutionary and historical aspects of the burden of malaria. Clinical microbiology reviews. 2002 Oct;15(4):564-94.
Lal AA, Rajvanshi H, Jayswar H, Das A, Bharti PK. Malaria elimination: Using past and present experience to make malaria-free India by 2030. Journal of Vector Borne Diseases. 2019 Jan 1;56(1):60-5.
World Health Organization. World Malaria Report https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2022 (2022)
Chandramohan D, Zongo I, Sagara I, Cairns M, Yerbanga RS, Diarra M, Nikièma F, Tapily A, Sompougdou F, Issiaka D, Zoungrana C. Seasonal malaria vaccination with or without seasonal malaria chemoprevention. New England Journal of Medicine. 2021 Sep 9;385(11):1005-17.
Sinnis P, Fidock DA. The RTS, S vaccine—a chance to regain the upper hand against malaria?. Cell. 2022 Mar 3;185(5):750-4.
Datoo MS, Natama HM, Somé A, Bellamy D, Traoré O, Rouamba T, Tahita MC, Ido NF, Yameogo P, Valia D, Millogo A. Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial. The Lancet Infectious Diseases. 2022 Dec 1;22(12):1728-36.
Bhargava S, Deshmukh R, Dewangan HK. Recent Advancement in Drug Development for Treating Malaria using Herbal Medicine and Nanotechnological Approach. Current Pharmaceutical Design. 2025 Jan;31(3):203-18.
Deshmukh R, Dewangan B, Harwansh RK, Agrawal R, Garg A, Chopra H. Current Trends in Nanotechnology-Based Drug Delivery Systems for the Diagnosis and Treatment of Malaria: A Review. Current Drug Delivery. 2025 Mar;22(3):310-31.
Sallam M, Al-Khatib AO, Al-Mahzoum KS, Abdelaziz DH, Sallam M. Current Developments in Malaria Vaccination: A Concise Review on Implementation, Challenges, and Future Directions. Clinical Pharmacology: Advances and Applications. 2025 Dec 31:29-47.
Ogwu MC, Izah SC. Technological Innovations in Tropical Diseases Treatment and Therapeutics. InTechnological Innovations for Managing Tropical Diseases 2025 Feb 20 (pp. 287-308). Cham: Springer Nature Switzerland.
Sanyaolu A, Marinkovic A, Prakash S, Balendra V, Shazley O, Gardellini T, Jan A, Younis K, Okorie C, Izurieta R. Emerging Molecular Mechanisms in Malaria Pathogenesis and Novel Therapeutic Approaches: A Focus on P. falciparum Malaria. Biomolecules. 2025 Jul 17;15(7):1038.
Zhao Y, Xiu R, Wang C, Wang J, Guo D, Luo W, Jiang S, Ge Z, Gao X. Nanoformulation-Based Transdermal Drug Delivery: A Paradigm Shift in Antiparasitic Therapy for Zoonotic Diseases. Pharmaceutics. 2025 Sep 18;17(9):1216.
Mate T, Bhagwat A, Auti V, Pawar S, Ambhore P. Pathophysiology of Malaria and Its Implications for Drug Resistance and Future Therapies.
Singh N, Bhatnagar N, Kuntal K, Rawat P. Review on Role of Biomarkers and Aptamers in Malaria Diagnostics Advances.
Wu D, Zeng H, Tan J, Xu Q, Khan FA, Pandupuspitasari NS, Yang S, Huang C. Repurposing Artemisinin-Based Drugs from Antimalarial to Pan-Therapeutic: Pharmacological Promise and Therapeutic Challenges. Drug Design, Development and Therapy. 2025 Dec 31:9199-226.
Babapour F, Khanabadi F, Fahimirad S, Hosseini SS, Elmi T. A Dendrimer-Based Dual Delivery System for Artesunate and Fluconazole: Effective Malaria Treatment in a Murine Model of Plasmodium berghei. Acta Tropica. 2025 May 21:107663.
Sun J, Xufeng J, Qiu Z, Gao Q, Zhu Z, He J, Gao S, Sui X. Artemisiae Annuae Herba: from anti-malarial legacy to emerging anti-cancer potential. Theranostics. 2025 Jun 20;15(15):7346.
Alburyhi MM, Saif AA, Noman MA. Compatibility Studies of Pyrimethamine with Pharmaceutical Excipients for the Development of Suppositories Novel Drug Delivery Systems. European Journal of Pharmaceutical and Medical Research. 2025;12(9):394-412.
Eltom EH, Alenezi BT, Soliman M, Jan M, Soliman A. Neglected Tropical Diseases: Current Treatment Challenges and Future Therapeutic Potentials. Prospects in Pharmaceutical Sciences. 2025 Apr 5;23(2):1-9.
Zhao Y, Xiu R, Wang C, Wang J, Guo D, Luo W, Jiang S, Ge Z, Gao X. Nanoparticle-Based Transdermal Drug Delivery: A Paradigm Shift in Antiparasitic Therapy for Zoonotic Diseases.
Alburyhi MM, Saif AA, Noman MA. Compatibility Studies of Sulfadoxine with Pharmaceutical Excipients for the Development of Suppositories Novel Drug Delivery Systems. World Journal of Pharmaceutical and Life Sciences. 2025;11(9):189-207.
Greenwood B, Cairns M, Chaponda M, Chico RM, Dicko A, Ouedraogo JB, Phiri KS, Ter Kuile FO, Chandramohan D. Combining malaria vaccination with chemoprevention: a promising new approach to malaria control. Malaria journal. 2021 Sep 6;20(1):361.
Wicht KJ, Mok S, Fidock DA. Molecular mechanisms of drug resistance in Plasmodium falciparum malaria. Annual review of microbiology. 2020 Sep 8;74(1):431-54.
Rasmussen C, Alonso P, Ringwald P. Current and emerging strategies to combat antimalarial resistance. Expert Review of Anti-infective Therapy. 2022 Mar 4;20(3):353-72.
Achan J, Talisuna AO, Erhart A, Yeka A, Tibenderana JK, Baliraine FN, Rosenthal PJ, D'Alessandro U. Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. Malaria journal. 2011 May 24;10(1):144.
White NJ. Qinghaosu (artemisinin): the price of success. Science. 2008 Apr 18;320(5874):330-4.
Plowe CV. Malaria chemoprevention and drug resistance: a review of the literature and policy implications. Malaria Journal. 2022 Mar 24;21(1):104.
van der Pluijm RW, Imwong M, Chau NH, Hoa NT, Thuy-Nhien NT, Thanh NV, Jittamala P, Hanboonkunupakarn B, Chutasmit K, Saelow C, Runjarern R. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. The Lancet infectious diseases. 2019 Sep 1;19(9):952-61.
Dhorda M, Amaratunga C, Dondorp AM. Artemisinin and multidrug-resistant Plasmodium falciparum–a threat for malaria control and elimination. Current opinion in infectious diseases. 2021 Oct 1;34(5):432-9.
Uwimana A, Legrand E, Stokes BH, Ndikumana JL, Warsame M, Umulisa N, Ngamije D, Munyaneza T, Mazarati JB, Munguti K, Campagne P. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nature medicine. 2020 Oct 1;26(10):1602-8.
Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana SI, Yamauchi M, Opio W, Emoto S, Anywar DA, Kimura E, Palacpac NM. Evidence of artemisinin-resistant malaria in Africa. New England Journal of Medicine. 2021 Sep 23;385(13):1163-71.
Straimer J, Gandhi P, Renner KC, Schmitt EK. High prevalence of Plasmodium falciparum K13 mutations in Rwanda is associated with slow parasite clearance after treatment with artemether-lumefantrine. The Journal of infectious diseases. 2022 Apr 15;225(8):1411-4.
Tumwebaze PK, Conrad MD, Okitwi M, Orena S, Byaruhanga O, Katairo T, Legac J, Garg S, Giesbrecht D, Smith SR, Ceja FG. Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda. Nature communications. 2022 Oct 26;13(1):6353.
Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, Kim S, Duru V, Bouchier C, Ma L, Lim P. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014 Jan 2;505(7481):50-5.
Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B, Sopha C. Spread of artemisinin resistance in Plasmodium falciparum malaria. New England Journal of Medicine. 2014 Jul 31;371(5):411-23.
Siddiqui FA, Liang X, Cui L. Plasmodium falciparum resistance to ACTs: Emergence, mechanisms, and outlook. International Journal for Parasitology: Drugs and Drug Resistance. 2021 Aug 1;16:102-18.
Straimer J, Gnädig NF, Witkowski B, Amaratunga C, Duru V, Ramadani AP, Dacheux M, Khim N, Zhang L, Lam S, Gregory PD. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science. 2015 Jan 23;347(6220):428-31.
Yang T, Yeoh LM, Tutor MV, Dixon MW, McMillan PJ, Xie SC, Bridgford JL, Gillett DL, Duffy MF, Ralph SA, McConville MJ. Decreased K13 abundance reduces hemoglobin catabolism and proteotoxic stress, underpinning artemisinin resistance. Cell reports. 2019 Nov 26;29(9):2917-28.
Birnbaum J, Scharf S, Schmidt S, Jonscher E, Hoeijmakers WA, Flemming S, Toenhake CG, Schmitt M, Sabitzki R, Bergmann B, Fröhlke U. A Kelch13-defined endocytosis pathway mediates artemisinin resistance in malaria parasites. Science. 2020 Jan 3;367(6473):51-9.
Mok S, Ashley EA, Ferreira PE, Zhu L, Lin Z, Yeo T, Chotivanich K, Imwong M, Pukrittayakamee S, Dhorda M, Nguon C. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science. 2015 Jan 23;347(6220):431-5.
Hott A, Casandra D, Sparks KN, Morton LC, Castanares GG, Rutter A, Kyle DE. Artemisinin-resistant Plasmodium falciparum parasites exhibit altered patterns of development in infected erythrocytes. Antimicrobial agents and chemotherapy. 2015 Jun;59(6):3156-67.
Xie SC, Ralph SA, Tilley L. K13, the cytostome, and artemisinin resistance. Trends in Parasitology. 2020 Jun 1;36(6):533-44.
Reyser T, Paloque L, Ouji M, Nguyen M, Ménard S, Witkowski B, Augereau JM, Benoit-Vical F. Identification of compounds active against quiescent artemisinin-resistant Plasmodium falciparum parasites via the quiescent-stage survival assay (QSA). Journal of Antimicrobial Chemotherapy. 2020 Oct;75(10):2826-34.
Connelly SV, Manzella-Lapeira J, Levine ZC, Brzostowski J, Krymskaya L, Rahman RS, Ellis AC, Amin SN, Sá JM, Wellems TE. Restructured mitochondrial-nuclear interaction in Plasmodium falciparum dormancy and persister survival after artemisinin exposure. MBio. 2021 Jul 7;12(3):10-128.
Mok S, Stokes BH, Gnädig NF, Ross LS, Yeo T, Amaratunga C, Allman E, Solyakov L, Bottrill AR, Tripathi J, Fairhurst RM. Artemisinin-resistant K13 mutations rewire Plasmodium falciparum’s intra-erythrocytic metabolic program to enhance survival. Nature communications. 2021 Jan 22;12(1):530.
Imwong M, Dhorda M, Tun KM, Thu AM, Phyo AP, Proux S, Suwannasin K, Kunasol C, Srisutham S, Duanguppama J, Vongpromek R. Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study. The Lancet Infectious Diseases. 2020 Dec 1;20(12):1470-80.
Stokes BH, Dhingra SK, Rubiano K, Mok S, Straimer J, Gnädig NF, Deni I, Schindler KA, Bath JR, Ward KE, Striepen J. Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness. Elife. 2021 Jul 19;10:e66277.
Demas AR, Sharma AI, Wong W, Early AM, Redmond S, Bopp S, Neafsey DE, Volkman SK, Hartl DL, Wirth DF. Mutations in Plasmodium falciparum actin-binding protein coronin confer reduced artemisinin susceptibility. Proceedings of the National Academy of Sciences. 2018 Dec 11;115(50):12799-804.
Sharma AI, Shin SH, Bopp S, Volkman SK, Hartl DL, Wirth DF. Genetic background and PfKelch13 affect artemisinin susceptibility of PfCoronin mutants in Plasmodium falciparum. PLoS Genetics. 2020 Dec 28;16(12):e1009266.
Henrici RC, van Schalkwyk DA, Sutherland CJ. Modification of pfap2μ and pfubp1 markedly reduces ring-stage susceptibility of Plasmodium falciparum to artemisinin in vitro. Antimicrobial agents and chemotherapy. 2019 Dec 20;64(1):10-128.
Amambua-Ngwa A, Amenga-Etego L, Kamau E, Amato R, Ghansah A, Golassa L, Randrianarivelojosia M, Ishengoma D, Apinjoh T, Maïga-Ascofaré O, Andagalu B. Major subpopulations of Plasmodium falciparum in sub-Saharan Africa. Science. 2019 Aug 23;365(6455):813-6.
Masserey T, Lee T, Golumbeanu M, Shattock AJ, Kelly SL, Hastings IM, Penny MA. The influence of biological, epidemiological, and treatment factors on the establishment and spread of drug-resistant Plasmodium falciparum. Elife. 2022 Jul 7;11:e77634.
Imwong M, Suwannasin K, Srisutham S, Vongpromek R, Promnarate C, Saejeng A, Phyo AP, Proux S, Pongvongsa T, Chea N, Miotto O. Evolution of multidrug resistance in Plasmodium falciparum: a longitudinal study of genetic resistance markers in the Greater Mekong Subregion. Antimicrobial agents and chemotherapy. 2021 Nov 17;65(12):10-128.
Amato R, Lim P, Miotto O, Amaratunga C, Dek D, Pearson RD, Almagro-Garcia J, Neal AT, Sreng S, Suon S, Drury E. Genetic markers associated with dihydroartemisinin–piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype–phenotype association study. The Lancet Infectious Diseases. 2017 Feb 1;17(2):164-73.
Witkowski B, Duru V, Khim N, Ross LS, Saintpierre B, Beghain J, Chy S, Kim S, Ke S, Kloeung N, Eam R. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype–genotype association study. The Lancet Infectious Diseases. 2017 Feb 1;17(2):174-83.
Chugh M, Sundararaman V, Kumar S, Reddy VS, Siddiqui WA, Stuart KD, Malhotra P. Protein complex directs hemoglobin-to-hemozoin formation in Plasmodium falciparum. Proceedings of the National Academy of Sciences. 2013 Apr 2;110(14):5392-7.
Rathore I, Mishra V, Patel C, Xiao H, Gustchina A, Wlodawer A, Yada RY, Bhaumik P. Activation mechanism of plasmepsins, pepsin‐like aspartic proteases from Plasmodium, follows a unique trans‐activation pathway. The FEBS journal. 2021 Jan;288(2):678-98.
Bopp S, Magistrado P, Wong W, Schaffner SF, Mukherjee A, Lim P, Dhorda M, Amaratunga C, Woodrow CJ, Ashley EA, White NJ. Plasmepsin II–III copy number accounts for bimodal piperaquine resistance among Cambodian Plasmodium falciparum. Nature communications. 2018 May 2;9(1):1769.
Dhingra SK, Redhi D, Combrinck JM, Yeo T, Okombo J, Henrich PP, Cowell AN, Gupta P, Stegman ML, Hoke JM, Cooper RA. A variant PfCRT isoform can contribute to Plasmodium falciparum resistance to the first-line partner drug piperaquine. MBio. 2017 Jul 5;8(3):10-128.
Ross LS, Dhingra SK, Mok S, Yeo T, Wicht KJ, Kümpornsin K, Takala-Harrison S, Witkowski B, Fairhurst RM, Ariey F, Menard D. Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine. Nature communications. 2018 Aug 17;9(1):3314.
Dhingra SK, Small-Saunders JL, Ménard D, Fidock DA. Plasmodium falciparum resistance to piperaquine driven by PfCRT. The Lancet Infectious Diseases. 2019 Nov 1;19(11):1168-9.
Hamilton WL, Amato R, van der Pluijm RW, Jacob CG, Quang HH, Thuy-Nhien NT, Hien TT, Hongvanthong B, Chindavongsa K, Mayxay M, Huy R. Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study. The Lancet Infectious Diseases. 2019 Sep 1;19(9):943-51.
Kim J, Tan YZ, Wicht KJ, Erramilli SK, Dhingra SK, Okombo J, Vendome J, Hagenah LM, Giacometti SI, Warren AL, Nosol K. Structure and drug resistance of the Plasmodium falciparum transporter PfCRT. Nature. 2019 Dec 12;576(7786):315-20.
Agrawal S, Moser KA, Morton L, Cummings MP, Parihar A, Dwivedi A, Shetty AC, Drabek EF, Jacob CG, Henrich PP, Parobek CM. Association of a novel mutation in the Plasmodium falciparum chloroquine resistance transporter with decreased piperaquine sensitivity. The Journal of infectious diseases. 2017 Aug 15;216(4):468-76.
Small-Saunders JL, Hagenah LM, Wicht KJ, Dhingra SK, Deni I, Kim J, Vendome J, Gil-Iturbe E, Roepe PD, Mehta M, Mancia F. Evidence for the early emergence of piperaquine-resistant Plasmodium falciparum malaria and modeling strategies to mitigate resistance. PLoS Pathogens. 2022 Feb 7;18(2):e1010278.
van Der Pluijm RW, Tripura R, Hoglund RM, Phyo AP, Lek D, Ul Islam A, Anvikar AR, Satpathi P, Satpathi S, Behera PK, Tripura A. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. The Lancet. 2020 Apr 25;395(10233):1345-60.
Boni MF, White NJ, Baird JK. The community as the patient in malaria-endemic areas: preempting drug resistance with multiple first-line therapies. PLoS medicine. 2016 Mar 29;13(3):e1001984.
Marwa K, Kapesa A, Baraka V, Konje E, Kidenya B, Mukonzo J, Kamugisha E, Swedberg G. Therapeutic efficacy of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Sub-Saharan Africa: A systematic review and meta-analysis. PloS one. 2022 Mar 10;17(3):e0264339.
Chotsiri P, Gutman JR, Ahmed R, Poespoprodjo JR, Syafruddin D, Khairallah C, Asih PB, L’lanziva A, Otieno K, Kariuki S, Ouma P. Piperaquine pharmacokinetics during intermittent preventive treatment for malaria in pregnancy. Antimicrobial agents and chemotherapy. 2021 Feb 17;65(3):10-128.
Qiu D, Pei JV, Rosling JE, Thathy V, Li D, Xue Y, Tanner JD, Penington JS, Aw YT, Aw JY, Xu G. A G358S mutation in the Plasmodium falciparum Na+ pump PfATP4 confers clinically-relevant resistance to cipargamin. Nature communications. 2022 Sep 30;13(1):5746.
Schmitt EK, Ndayisaba G, Yeka A, Asante KP, Grobusch MP, Karita E, Mugerwa H, Asiimwe S, Oduro A, Fofana B, Doumbia S. Efficacy of cipargamin (KAE609) in a randomized, phase II dose-escalation study in adults in sub-Saharan Africa with uncomplicated Plasmodium falciparum malaria. Clinical Infectious Diseases. 2022 May 15;74(10):1831-9.
Duffey M, Blasco B, Burrows JN, Wells TN, Fidock DA, Leroy D. Assessing risks of Plasmodium falciparum resistance to select next-generation antimalarials. Trends in parasitology. 2021 Aug 1;37(8):709-21.
Tse EG, Korsik M, Todd MH. The past, present and future of anti-malarial medicines. Malaria journal. 2019 Mar 22;18(1):93.
Guantai E, Chibale K. How can natural products serve as a viable source of lead compounds for the development of new/novel anti-malarials?. Malaria Journal. 2011 Mar 15;10(Suppl 1):S2.
Plouffe D, Brinker A, McNamara C, Henson K, Kato N, Kuhen K, Nagle A, Adrián F, Matzen JT, Anderson P, Nam TG. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proceedings of the National Academy of Sciences. 2008 Jul 1;105(26):9059-64.
Guiguemde WA, Shelat AA, Bouck D, Duffy S, Crowther GJ, Davis PH, Smithson DC, Connelly M, Clark J, Zhu F, Jiménez-Díaz MB. Chemical genetics of Plasmodium falciparum. Nature. 2010 May 20;465(7296):311-5.
Miguel-Blanco C, Molina I, Bardera AI, Díaz B, de Las Heras L, Lozano S, González C, Rodrigues J, Delves MJ, Ruecker A, Colmenarejo G. Hundreds of dual-stage antimalarial molecules discovered by a functional gametocyte screen. Nature communications. 2017 May 17;8(1):15160.
Gamo FJ, Sanz LM, Vidal J, De Cozar C, Alvarez E, Lavandera JL, Vanderwall DE, Green DV, Kumar V, Hasan S, Brown JR. Thousands of chemical starting points for antimalarial lead identification. Nature. 2010 May 20;465(7296):305-10.
Hovlid ML, Winzeler EA. Phenotypic screens in antimalarial drug discovery. Trends in parasitology. 2016 Sep 1;32(9):697-707.
Delves MJ, Miguel-Blanco C, Matthews H, Molina I, Ruecker A, Yahiya S, Straschil U, Abraham M, León ML, Fischer OJ, Rueda-Zubiaurre A. A high throughput screen for next-generation leads targeting malaria parasite transmission. Nature communications. 2018 Sep 18;9(1):3805.
Antonova-Koch Y, Meister S, Abraham M, Luth MR, Ottilie S, Lukens AK, Sakata-Kato T, Vanaerschot M, Owen E, Jado JC, Maher SP. Open-source discovery of chemical leads for next-generation chemoprotective antimalarials. Science. 2018 Dec 7;362(6419):eaat9446.
Abraham M, Gagaring K, Martino ML, Vanaerschot M, Plouffe DM, Calla J, Godinez-Macias KP, Du AY, Wree M, Antonova-Koch Y, Eribez K. Probing the open global health chemical diversity library for multistage-active starting points for next-generation antimalarials. ACS Infectious Diseases. 2020 Feb 20;6(4):613-28.
Guiguemde WA, Shelat AA, Garcia-Bustos JF, Diagana TT, Gamo FJ, Guy RK. Global phenotypic screening for antimalarials. Chemistry & biology. 2012 Jan 27;19(1):116-29.
White NJ, Krishna S. Treatment of malaria: some considerations and limitations of the current methods of assessment. Transactions of the Royal Society of tropical medicine and hygiene. 1989 Nov 1;83(6):767-77.
Mbanefo A, Kumar N. Evaluation of malaria diagnostic methods as a key for successful control and elimination programs. Tropical medicine and infectious disease. 2020 Jun 19;5(2):102.
Agbata BC, Kovaci S, Agbebaku DF, Dervishi R, Abah E, Mbah GC, Emadifar H, Smerat A. Fractional-order model of malaria incorporating treatment and prevention strategies. Scientific Reports. 2025 Aug 11;15(1):29290.
Atusingwize E, Deane K, Musoke D. Social determinants of malaria in low-and middle-income countries: a mixed-methods systematic review. Malaria Journal. 2025 May 26;24(1):165.
Abdul-Rahman T, Ajetunmobi OA, Bamigbade GB, Ayesiga I, Shah MH, Rumide TS, Adesina AB, Adeshina GA, Oni OE, Christian BI, Aborode AT. Improving diagnostics and surveillance of malaria among displaced people in Africa. International Journal for Equity in Health. 2025 Jan 21;24(1):22.
Babawo LS, Kpaka RB, Sesay DK. Assessment of malaria treatment interventions: a critical analysis of government initiatives and causes of treatment failure at Port Loko Government Hospital, Sierra Leone. Malaria Journal. 2025 Mar 14;24(1):83.
Onukansi FO, Anokwuru CC, Eneh SC, Odey GO, Onah DO, Sokunbi T, Innocent DC, Dozie UW, Umoke PC, Ojo TO, Ezejindu CN. Investing in traditional medicine: leveraging evidence and innovative research to strengthen the fight against malaria in Nigeria. Malaria Journal. 2025 Jul 15;24(1):232.
Ampomah IG, Devine S, Ampomah GA, Emeto TI. Exploring the contribution of integrated healthcare practices to malaria control in Ghana: perspectives of medical herbalists. BMC complementary medicine and therapies. 2025 Jan 14;25(1):11.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Reeshita Jhanak
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
10.55544/jrasb
editor@jrasb.com or mailtojrasb@gmail.com | 
+91-8874396939
This work is licensed under a 